Source-grounded facts extracted from BICYCLE THERAPEUTICS PLC's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
BICYCLE THERAPEUTICS PLC shareholders approved To approve the directors' remuneration policy at the 2026-06-17 meeting.
“Proposal 9 – To approve the directors’ remuneration policy, which policy is set forth in the Company’s definitive proxy statement, and which will take effect immediately after the end of the AGM For Against Vote Withheld/Abstain 48,238,031 1,293,722 165,155”
BICYCLE THERAPEUTICS PLC shareholders approved To approve the directors' remuneration report for the year ended December 31, 2025 (excluding the remuneration policy) at the 2026-06-17 meeting.
“Proposal 8 – To approve the directors’ remuneration report for the year ended December 31, 2025, which report is set forth in the Company’s definitive proxy statement (excluding the directors’ remuneration policy) For Against Vote Withheld/Abstain 48,741,517 792,394 162,997”
BICYCLE THERAPEUTICS PLC shareholders approved To receive and adopt the Company's U.K. statutory annual accounts and reports for the year ended December 31, 2025 at the 2026-06-17 meeting.
“Proposal 7 – To receive and adopt the Company’s U.K. statutory annual accounts and reports for the year ended December 31, 2025. For Against Vote Withheld/Abstain 49,138,590 553,781 4,537”
BICYCLE THERAPEUTICS PLC shareholders approved To authorize the Audit Committee to determine the Company's U.K. statutory auditors' remuneration for the year ending December 31, 2026 at the 2026-06-17 meeting.
“Proposal 6 – To authorize the Audit Committee of the Company’s Board of Directors to determine the Company’s U.K. statutory auditors’ remuneration for the year ending December 31, 2026 For Against Vote Withheld/Abstain 49,493,240 47,269 156,399”
BICYCLE THERAPEUTICS PLC shareholders approved To re-appoint PricewaterhouseCoopers LLP as the Company's U.K. statutory auditors to hold office until the conclusion of the next annual general meeting at the 2026-06-17 meeting.
“Proposal 5 – To re-appoint PricewaterhouseCoopers LLP, a limited liability partnership organized under the laws of England, as the Company’s U.K. statutory auditors, to hold office until the conclusion of the next annual general meeting of shareholders For Against Vote Withheld/Abstain 49,441,337 235,008 20,563”
BICYCLE THERAPEUTICS PLC shareholders approved To ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026 at the 2026-06-17 meeting.
“Proposal 4 – To ratify the appointment of PricewaterhouseCoopers LLP, a limited liability partnership organized under the laws of England, as the Company’s independent registered public accounting firm for the year ending December 31, 2026 For Against Vote Withheld/Abstain 49,445,128 232,627 19,153”
BICYCLE THERAPEUTICS PLC shareholders approved To approve, on an advisory basis, the compensation of the Company's named executive officers at the 2026-06-17 meeting.
“Proposal 3 – To approve, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in the Company’s definitive proxy statement For Against Vote Withheld/Abstain 48,748,743 785,032 163,133”
BICYCLE THERAPEUTICS PLC shareholders approved To re-elect as a director Hervé Hoppenot at the 2026-06-17 meeting.
“Proposal 2 – To re-elect as a director Hervé Hoppenot For Against Vote Withheld/Abstain 49,284,459 250,669 161,780”
BICYCLE THERAPEUTICS PLC shareholders approved To re-elect as a director Felix Baker at the 2026-06-17 meeting.
“Proposal 1 – To re-elect as a director Felix Baker For Against Vote Withheld/Abstain 46,171,302 3,364,113 161,493”
BICYCLE THERAPEUTICS PLC reported financial results for the fiscal quarter ended March 31, 2026.
“On April 30, 2026, Bicycle Therapeutics plc issued a press release announcing financial results for the fiscal quarter ended March 31, 2026 and other business highlights.”
BICYCLE THERAPEUTICS PLC reported financial results for the fourth quarter and full year ended December 31, 2025.
“On March 17, 2026, Bicycle Therapeutics plc (the “Company”) issued a press release announcing financial results for the fiscal quarter and the year ended December 31, 2025 and other business highlights.”
Santiago Arroyo resigned as Chief Development Officer at BICYCLE THERAPEUTICS PLC.
“Santiago Arroyo, M.D., Ph.D., notified the Board of his resignation as the Company's Chief Development Officer, effective March 24, 2025.”
Richard Kender resigned as Director at BICYCLE THERAPEUTICS PLC.
“On March 27, 2025, the Company also announced that Pierre Legault, MBA, CPA, and Richard Kender, MBA, would not be standing for re-election at the 2025 Annual Meeting, and that each of Mr. Legault and Mr. Kender would retire from the Board effective immediately following the 2025 Annual Meeting.”
Pierre Legault resigned as Director at BICYCLE THERAPEUTICS PLC.
“On March 27, 2025, the Company also announced that Pierre Legault, MBA, CPA, and Richard Kender, MBA, would not be standing for re-election at the 2025 Annual Meeting, and that each of Mr. Legault and Mr. Kender would retire from the Board effective immediately following the 2025 Annual Meeting.”
Alessandro Riva was appointed as Director at BICYCLE THERAPEUTICS PLC.
“appointed Alessandro Riva, M.D., to the Board and the Scientific Committee of the Board, effective as of the close of business on March 25, 2025, New York City time.”
BICYCLE THERAPEUTICS PLC shareholders approved To adopt the new articles of association in substitution for, and to the exclusion of, the Company's existing articles of association. at the 2024-05-16 meeting.
“Proposal 11 – To adopt the new articles of association in substitution for, and to the exclusion of, the Company’s existing articles of association. For Against Vote Withheld/Abstain 37,371,711 15,138 11,258”
BICYCLE THERAPEUTICS PLC shareholders approved To authorize the Board to allot equity securities for cash up to a maximum aggregate nominal amount of £1,000,000 pursuant to the authorization in Resolution 9 as if U.K. statutory pre-emption rights did not apply. at the 2024-05-16 meeting.
“Proposal 10 – To authorize the Board to allot equity securities for cash up to a maximum aggregate nominal amount of £1,000,000 pursuant to the authorization in Resolution 9 as if U.K. statutory pre-emption rights did not apply. For Against Vote Withheld/Abstain 32,350,797 4,154,715 892,595”
BICYCLE THERAPEUTICS PLC shareholders approved To authorize the Board to allot shares in the Company or to grant rights to subscribe for or to convert any security into shares in the Company up to a maximum aggregate nominal amount of £1,000,000. at the 2024-05-16 meeting.
“Proposal 9 – To authorize the Board to allot shares in the Company or to grant rights to subscribe for or to convert any security into shares in the Company up to a maximum aggregate nominal amount of £1,000,000. For Against Vote Withheld/Abstain 33,241,556 4,146,578 9,973”
BICYCLE THERAPEUTICS PLC shareholders approved To approve the directors' remuneration report for the year ended December 31, 2023. at the 2024-05-16 meeting.
“Proposal 8 – To approve the directors’ remuneration report for the year ended December 31, 2023. For Against Vote Withheld/Abstain 36,200,790 1,188,057 9,260”
BICYCLE THERAPEUTICS PLC shareholders approved To receive and adopt the Company's U.K. statutory annual accounts and reports for the year ended December 31, 2023. at the 2024-05-16 meeting.
“Proposal 7 – To receive and adopt the Company’s U.K. statutory annual accounts and reports for the year ended December 31, 2023. For Against Vote Withheld/Abstain 36,494,043 896,166 7,898”
BICYCLE THERAPEUTICS PLC shareholders approved To authorize the Audit Committee of the Company's Board of Directors to determine the Company's U.K. statutory auditors' remuneration for the year ending December 31, 2024. at the 2024-05-16 meeting.
“Proposal 6 – To authorize the Audit Committee of the Company’s Board of Directors (the “Board”) to determine the Company’s U.K. statutory auditors’ remuneration for the year ending December 31, 2024. For Against Vote Withheld/Abstain 37,376,455 14,150 7,502”
BICYCLE THERAPEUTICS PLC shareholders approved To re-appoint PricewaterhouseCoopers LLP, a limited liability partnership organized under the laws of England, as the Company's U.K. statutory auditors, to hold office until the conclusion of the next annual general meeting of shareholders. at the 2024-05-16 meeting.
“Proposal 5 – To re-appoint PricewaterhouseCoopers LLP, a limited liability partnership organized under the laws of England, as the Company’s U.K. statutory auditors, to hold office until the conclusion of the next annual general meeting of shareholders. For Against Vote Withheld/Abstain 37,376,531 14,071 7,505”
BICYCLE THERAPEUTICS PLC shareholders approved To ratify the appointment of PricewaterhouseCoopers LLP, a limited liability partnership organized under the laws of England, as the Company's U.S. independent registered public accounting firm for the year ending December 31, 2024. at the 2024-05-16 meeting.
“Proposal 4 – To ratify the appointment of PricewaterhouseCoopers LLP, a limited liability partnership organized under the laws of England, as the Company’s U.S. independent registered public accounting firm for the year ending December 31, 2024. For Against Vote Withheld/Abstain 37,376,526 14,076 7,505”
BICYCLE THERAPEUTICS PLC shareholders approved To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Company's definitive proxy statement. at the 2024-05-16 meeting.
“Proposal 3 – To approve, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in the Company’s definitive proxy statement. For Against Vote Withheld/Abstain 36,186,115 1,202,477 9,515”
BICYCLE THERAPEUTICS PLC shareholders approved To re-elect as a director Jose-Carlos Gutierrez-Ramos. at the 2024-05-16 meeting.
“Proposal 2 – To re-elect as a director Jose-Carlos Gutierrez-Ramos. For Against Vote Withheld/Abstain 35,019,069 2,371,385 7,653”
BICYCLE THERAPEUTICS PLC shareholders approved To re-elect as a director Kevin Lee. at the 2024-05-16 meeting.
“Proposal 1 – To re-elect as a director Kevin Lee. For Against Vote Withheld/Abstain 36,413,260 977,286 7,561”
BICYCLE THERAPEUTICS PLC reported first quarter ended March 31, 2024 results: net income Net loss was $26.6 million, EPS $(0.62) basic and diluted net loss per share.
“Net loss was $26.6 million, or $(0.62) basic and diluted net loss per share, for the three months ended March 31, 2024”
Felix J. Baker was appointed as Class I Director at BICYCLE THERAPEUTICS PLC.
“On April 16, 2024, the Board , upon the recommendation of the Nominating and Corporate Governance Committee of the Company (the “ NCGC ”), appointed Felix J. Baker, Ph.D. to the Board, effective as of April 18, 2024, New York City time.”
Veronica Jordan resigned as Class I Director at BICYCLE THERAPEUTICS PLC.
“On April 16, 2024, Veronica Jordan, Ph.D. notified the Board of Directors of the Company (the “ Board ”) of her decision to resign as a Class I director of the Company and as the Chair of the Compensation Committee of the Board and as a member of the Audit Committee of the Board, effective as of the close of business on April 17, 2024, New York City time.”
BICYCLE THERAPEUTICS PLC reported financial results for the fiscal quarter and the year ended December 31, 2023.
“On February 20, 2024, Bicycle Therapeutics plc (the “Company”) issued a press release announcing financial results for the fiscal quarter and the year ended December 31, 2023 and other business highlights.”
Stephen Sands was appointed as Director at BICYCLE THERAPEUTICS PLC.
“On February 20, 2024, the Board of Directors (the “Board”) of the Company, upon the recommendation of the Nominating & Corporate Governance Committee of the Board, appointed Stephen Sands to the Board, effective as of the close of business on February 20, 2024, New York City time.”
BICYCLE THERAPEUTICS PLC reported financial results for third quarter ended September 30, 2023.
“On November 2, 2023, Bicycle Therapeutics plc issued a press release announcing financial results for the fiscal quarter ended September 30, 2023 and other business highlights.”
BICYCLE THERAPEUTICS PLC entered into Underwriting Agreement with Goldman Sachs & Co. LLC, Jefferies LLC and SVB Securities LLC (Representatives) valued at approximately $187.3 million (effective 2023-07-12).
“On July 12, 2023, Bicycle Therapeutics plc (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with Goldman Sachs & Co. LLC, Jefferies LLC and SVB Securities LLC (the “ Representatives ”), as representatives of the several underwriters named therein (collectively, the “ Underwriters ”), pursuant to which the Company agreed to issue and sell 9,411,766 American Depositary Shares (“ ADSs ”), each representing one of the Company’s ordinary shares, nominal value £0.01 per share, and, in lieu of ADSs to investors that so choose, non-voting ordinary shares, nominal value £0.01 per share (“ Non-Voting Ordinary Shares ”), each at a public offering price of $21.25 per share (the “ Offering ”). The net proceeds to the Company from the Offering are expected to be approximately $187.3 million”
Travis Thompson was appointed as Chief Accounting Officer at BICYCLE THERAPEUTICS PLC.
“the Board appointed Travis Thompson as the Company’s Chief Accounting Officer and principal accounting officer, effective as of the Transition Date”
Alethia Young was appointed as Chief Financial Officer at BICYCLE THERAPEUTICS PLC.
“the Board of Directors (the “ Board ”) of Bicycle Therapeutics plc (the “ Company ”) appointed Alethia Young as Chief Financial Officer and principal financial officer, effective on or about July 17, 2023”
BICYCLE THERAPEUTICS PLC shareholders approved To approve the directors' remuneration policy, which will take effect immediately after the end of the AGM. at the 2023-06-13 meeting.
“Proposal 10 -– To approve the directors’ remuneration policy, which will take effect immediately after the end of the AGM. For Against Vote Withheld/Abstain 26,075,659 1,971,866 9,396”
BICYCLE THERAPEUTICS PLC shareholders approved To approve the directors' remuneration report for the year ended December 31, 2022 (excluding the directors' remuneration policy). at the 2023-06-13 meeting.
“Proposal 9 – To approve the directors’ remuneration report for the year ended December 31, 2022 (excluding the directors' remuneration policy). For Against Vote Withheld/Abstain 26,084,674 1,964,069 8,178”
BICYCLE THERAPEUTICS PLC shareholders approved To receive and adopt the Company's U.K. statutory annual accounts and reports for the year ended December 31, 2022. at the 2023-06-13 meeting.
“Proposal 8 – To receive and adopt the Company’s U.K. statutory annual accounts and reports for the year ended December 31, 2022. For Against Vote Withheld/Abstain 28,047,438 1,339 8,144”
BICYCLE THERAPEUTICS PLC shareholders approved To authorize the Audit Committee to determine the Company's U.K. statutory auditors' remuneration for the year ending December 31, 2023. at the 2023-06-13 meeting.
“Proposal 7 – To authorize the Audit Committee to determine the Company’s U.K. statutory auditors’ remuneration for the year ending December 31, 2023. For Against Vote Withheld/Abstain 28,047,978 1,381 7,562”
BICYCLE THERAPEUTICS PLC shareholders approved To re-appoint PricewaterhouseCoopers LLP, a limited liability partnership organized under the laws of England, as the Company's U.K. statutory auditors, to hold office until the conclusion of the next annual general meeting of shareholders. at the 2023-06-13 meeting.
“Proposal 6 – To re-appoint PricewaterhouseCoopers LLP, a limited liability partnership organized under the laws of England, as the Company’s U.K. statutory auditors, to hold office until the conclusion of the next annual general meeting of shareholders. For Against Vote Withheld/Abstain 28,045,082 4,528 7,311”
BICYCLE THERAPEUTICS PLC shareholders approved To ratify the appointment of PricewaterhouseCoopers LLP, a limited liability partnership organized under the laws of England, as the Company's U.S. independent registered public accounting firm for the year ending December 31, 2023. at the 2023-06-13 meeting.
“Proposal 5 – To ratify the appointment of PricewaterhouseCoopers LLP, a limited liability partnership organized under the laws of England, as the Company’s U.S. independent registered public accounting firm for the year ending December 31, 2023. For Against Vote Withheld/Abstain 28,045,153 4,500 7,268”
BICYCLE THERAPEUTICS PLC shareholders approved To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Company's definitive proxy statement. at the 2023-06-13 meeting.
“Proposal 4 – To approve, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in the Company’s definitive proxy statement. For Against Vote Withheld/Abstain 26,083,084 1,965,019 8,818”
BICYCLE THERAPEUTICS PLC shareholders approved To re-elect as a director Sir Greg Winter. at the 2023-06-13 meeting.
“Proposal 3 – To re-elect as a director Sir Greg Winter. For Against Vote Withheld/Abstain 27,238,892 632,657 185,372”
BICYCLE THERAPEUTICS PLC shareholders approved To re-elect as a director Veronica Jordan. at the 2023-06-13 meeting.
“Proposal 2 – To re-elect as a director Veronica Jordan. For Against Vote Withheld/Abstain 27,943,943 105,672 7,306”
BICYCLE THERAPEUTICS PLC shareholders approved To re-elect as a director Janice Bourque. at the 2023-06-13 meeting.
“Proposal 1 – To re-elect as a director Janice Bourque. For Against Vote Withheld/Abstain 27,895,136 154,479 7,306”
BICYCLE THERAPEUTICS PLC entered into Collaboration and License Agreement with Bayer Consumer Care AG valued at Upfront payment of $45 million, with potential milestone and royalty payments up to $1.7 billion (effective 2023-05-04).
“On May 4, 2023, BicycleTx Limited (the “Company”) and Bayer Consumer Care AG (“Bayer”) entered into a collaboration and license agreement (the “Collaboration Agreement”), pursuant to which the parties will perform research and discovery activities under a mutually agreed upon research plan during a research term of up to a specified number of years per target program to generate radiopharmaceutical compounds incorporating optimized Bicycle constructs directed to two specified targets, under the oversight of a joint steering committee.”
BICYCLE THERAPEUTICS PLC reported financial results for the first quarter ended March 31, 2023.
“Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) technology, today reported financial results for the first quarter ended March 31, 2023 and provided recent corporate updates.”
BICYCLE THERAPEUTICS PLC entered into Collaboration Agreement with Novartis Pharma AG valued at $50 million (effective 2023-03-27).
“On March 27, 2023, BicycleTx, Limited. (the “Company”) and Novartis Pharma AG (“Novartis”) entered into a collaboration and license agreement (the “Collaboration Agreement”)”
BICYCLE THERAPEUTICS PLC reported the fourth quarter and full year ended December 31, 2022 results: net income Net loss was $30.0 million, or $(1.01) basic and diluted net loss per share, for the three months ended December 31, 202, EPS $(1.01) basic and diluted net loss per share.
“On February 28, 2023, Bicycle Therapeutics plc issued a press release announcing financial results for the fiscal quarter and the year ended December 31, 2022 and other business highlights.”
BICYCLE THERAPEUTICS PLC reported the third quarter ended September 30, 2022 results: net income Net loss was $28.3 million, or $(0.96) basic and diluted net loss per share, EPS $(0.96) basic and diluted net loss per share.
“Bicycle Therapeutics plc (the "Company") issued a press release announcing financial results for the fiscal quarter ended September 30, 2022”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.